Open AccessCARDIOVASCULAR EFFECTS OF INDACATEROL IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Author(s) -
Н. Ш. Загидуллин,
Ю. Ф. Сафина,
Rustem Zulkarneev,
Ю. Г. Азнабаева,
Г. М. Нуртдинова,
Ш. З. Загидуллин
Publication year - 2016
Publication title -
pulʹmonologiâ
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.126
H-Index - 6
eISSN - 2541-9617
pISSN - 0869-0189
DOI - 10.18093/0869-0189-2016-26-5-570-577
Subject(s) - indacaterol , medicine , copd , cardiology , contractility , prospective cohort study , pulse wave velocity , lung function , anesthesia , lung , blood pressure
The aim of this study was to investigate cardiovascular effects of the inhaled betaagonist indacaterol in COPD patients. Methods. In this prospective reallife nonrandomized study, 25 patients with moderate COPD were treated with indacaterol for 3 months. Lung function testing, echocardiography, measurements of arterial stiffness, pulse wave velocity, heart rate variability and compliance were done. Results. Tendencies to the heart size reduction, decrease in the pulmonary artery pressure, improvement in the heart contractility and autonomous functions were seen after 3 months of the therapy. The lung function parameters did not change reliably. These changes were more significant in compliant patients (18 of 25). Conclusions. Therapy of COPD patients with indacaterol 150 mg daily improved the cardiovascular status.